简繁EN
Antengene

Company Introduction

3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both next-generation biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

MORE

April 2021

04
04
04
04
04
04
04
March 2020
October 2020
November 2020
December 2020
January 2021
March 2021
April 2021

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Partner

  • Envafolimab
  • PD-L1
  • Worldwide

  • MSI-H/dMMR advanced cancer (mono, 2L+)

  • Advanced BTC (combo with chemo vs. chemo, 1L)

  • NSCLC (vs standard treatment)

  • NSCLC (combo with chidamide, 2L+)

  • UC (mono vs. BSC, 1L maintenance, MRCT)

  • G/GEJ advanced cancer (combo with chemo, 1L)

  • TMB-H advanced cancer (mono, 2L+)

  • EC (mono and combo with lenvatinib, 2L+)

  • NSCLC, HCC, RCC (combo with lenvatinib)

  • HCC, CRC, NSCLC (combo with BD0801)

  • Alphamab Group

    Simcere Group
    (CSO)

    TRACON
    (Sarcoma, Phase II)

MORE

  • 3D189
  • WT1
  • Greater China

  • Multiple indications

  • SELLAS Group

MORE

  • 3D229
  • GAS6/AXL
  • Greater China

  • Healthy Volunteers

  • NSCLC/RCC/UC

  • PROC

    (MRCT)

  • Aravive

MORE

  • 3D1001
  • COX-2
  • China

  • Post-surgical dental pain/cancer pain

  • Haihe Biopharma Group

MORE

  • 3D1002
  • EP-4
  • China

  • Cancer pain / osteoarthritis

  • Haihe Biopharma Group

MORE

  • 3D185
  • FGFR1/2/3
  • Worldwide

  • Locally advanced or metastatic solid tumors

  • Haihe Biopharma Group & SIMM

MORE

  • 3D011
  • TKI prodrug
  • Worldwide

  • Advanced malignant solid tumors

MORE

  • 3D197
  • CD47
  • Greater China

  • Multiple indications

  • ImmuneOncia

MORE

  • 3D057
  • CD3+PD-L1
  • Greater China + Worldwide Priority Transfer right

  • Multiple indications

  • Y-Biologics

MORE

  • 3D059
  • WT1
  • Greater China

  • Multiple indications

  • SELLAS Group

MORE

  • 3D060
  • Sema4D
  • Worldwide

  • Multiple indications

MORE

  • 3D062
  • KRAS
  • Worldwide

  • Multiple indications

MORE

Pipeline

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062

CEO MESSAGE

"With the increasing incidence of cancer, cancer has become one of the major public health problems facing mankind; it not only poses a major threat to human health, but also causes a serious burden to economic and social development.

With commitment to the R&D and commercialization of a next-generation of innovative immuno-oncology drugs, 3D Medicines hopes to provide cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, thus helping them to live longer and better."


-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE

Copyright © 3D Medicines Inc. All Rights Reserved